Recruiting

Phase 2

RMT & Durvalumab, ChemoRMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Sponsor:

Masonic Cancer Center, University of Minnesota

Code:

NCT04105270

Conditions

Adenocarcinoma of Lung

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Oral Restorative Microbiota Therapy (RMT) Capsules

Durvalumab 1500 mg IV

Cisplatin/pemetrexed or Carboplatin/pemetrexed

Placebo

Study Details

Brief summary:

This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)

Conditions

Adenocarcinoma of Lung

Lung Cancer

Study ID

NCT04105270

Start date

Nov 30, 2022

Status verified date

Sep, 2025

Completion date

Jan, 2028

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma of the lung that is unresectable stage IIIB/C or stage IV, does not have an EGFR sensitizing (activating) mutation or ALK or ROS1 translocation. BRAF, RET, NTRK, MET ex 14 splice site mutation
Measurable disease based on RECIST 1.1
Tumor sample requirements

Mandatory provision of an unstained, archived tumor tissue sample in a quantity sufficient to allow for biomarker and genomic analysis. A minimum of 10 unstained slides should be available for evaluation.
Known PD-L1 TC expression status assayed by Ventana SP263. Patients who have known PDL-1 as assayed by PharmDx 22C3 assay may be eligible; however, available archival tissue will be used to assay with Ventana SP263 test.
Prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted as long as it has been >6 months from last dose at the time of enrollment. Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g. by local surgery or radiotherapy). Prior systemic therapy for advanced/metastatic NSCLC makes the patient ineligible for this study.
Patients with treated brain metastasis are eligible as long as they have stable symptoms, are more than 2 weeks from completion of therapy, and do not require more than 10mg of daily prednisone or equivalent.
ECOG Performance status of 0 or 1
Body weight of >30 kg
Adequate organ function within 14 days of study enrollment defined as:

Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count ≥1,500/mcL
Platelets ≥ 100,000/mcL
Total bilirubin ≤1.5x upper limit of normal (ULN) - this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
AST (SGOT) and ALT (SGPT) ≤2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤5x ULN
Measured creatinine clearance (CL) >40 mL/min or calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
Expected life expectancy of at least 12 weeks in the opinion of the enrolling investigator as documented in the medical record
Women of childbearing potential and men with partners of child-bearing potential must agree to use effective contraception for the time of screening to the duration of treatment and 3 months after the last dose of study drug
Provide voluntary written consent prior to the performance of any research related tests or procedures.

Exclusion Criteria:

Not pregnant or breast feeding. Evidence of post-menopausal status, or negative urine or serum pregnancy test for female pre-menopausal patients. Women will be considered postmenopausal if they have amenorrhea for 12 months without an alternative medical explanation
Dysphagia or inability to swallow medications
Squamous cell, large cell, or NSCLC NOS (not otherwise specified) histology or mixed tumors
Has untreated brain metastasis or active leptomeningeal carcinomatosis
Has a known sensitivity to any component of therapeutic agents used in this study
Receipt of any immunotherapy or investigational drug within 4 weeks prior to the first dose of study drug; and in the case of monoclonal antibodies 6 weeks prior to the first dose of study drug
Prior treatment with any other anti-PD-1, or PD-L1, including durvalumab or an anti-PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors except as adjuvant therapy for NSCLC so long as it has been greater than six months since the last treatment
Current or prior use of immunosuppressive medication within 28 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug
Active or prior documented autoimmune disease within the past 2 years requiring systemic treatment (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
Active documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) who require immunosuppression or patients who exceed 10 mg/day of prednisone, or an equivalent corticosteroid are excluded
History of primary immunodeficiency
History of organ transplant that requires therapeutic immunosuppression
Taking daily probiotics (patients with last probiotic > 4weeks prior to first dose of RMT are eligible)
History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive) who are on anti-retroviral treatment for < 6 months and absolute CD4 count<500 (patients with HIV not meeting these criteria are eligible)
Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg, and positive hepatitis B virus quantification assay (patients with history of Hepatitis B who have seroconversion i.e. Hepatitis B core antibody positive and Hepatitis B surface antibody positive are eligible). Active Hepatitis C is defined by a known positive Hep C Ab result and positive quantitative HCV RNA results (Patients with Hepatitis C who are on anti-viral suppressive therapy and negative quantitative HCV RNA results are eligible)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses
Myocardial infarction or stroke within 3 months prior to enrollment
History of systolic or diastolic heart failure with New York Heart Association (NYHA) class III or IV symptoms (refer to Appendix II)
Has active or prior history of (non-infectious) pneumonitis that required steroids or patients with interstitial lung disease
Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent
Known history of active tuberculosis. Patients with prior history of latent TB could be included if they have been treated previously with isoniazid.
Patients who are on chronic systemic antibiotic therapy (antibiotics for ≥60 consecutive days within 12 weeks of enrollment). Patients who receive systemic antibiotics between enrollment and start of RMT are eligible
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving RMT
History of another primary malignancy (excluding non-melanoma skin cancer) within 5 years prior to starting RMT, except if the patient has undergone potentially curative therapy with no evidence of disease recurrence for 5 years since initiation of that therapy
Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results

Study Design

Enrollment

82 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm A (RMT)

experimental: Arm B (Placebo)

experimental: Safety Run-in

10 patients are enrolled in this safety run-in arm. Patients are directly assigned to RMT treatment arm. After safety- run-in period of 4 weeks after the first dose of RMT, in the 10 patients if no new safety signal are seen enrollment moves to randomization

Interventions

Oral Restorative Microbiota Therapy (RMT) Capsules

Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly

Durvalumab 1500 mg IV

Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab

Cisplatin/pemetrexed or Carboplatin/pemetrexed

Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W

Placebo

Sixteen doses of oral placebo capsules given weekly

Primary outcome measure

Number of patients experiencing Progression Free Survival (PFS) [ Time Frame: 3 Years ]
Safety and tolerability of RMT [ Time Frame: 2 Years ]

Central Contacts and Locations

Central contacts

Cancer Center Clinical Trials Office

612 624 2620 ccinfo@umn.edu

Locations

MNCCTN Essentia Health St. Joseph's Brainerd Medical Center

Recruiting

Brainerd, Minnesota, United States, 56401

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

MNCCTN Essentia Health Deer River

Recruiting

Deer River, Minnesota, United States, 56636

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

MNCCTN Essentia Health St. Mary's Detroit Lakes Clinic

Recruiting

Detroit Lakes, Minnesota, United States, 56501

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

MNCCTN Essentia Health Duluth

Recruiting

Duluth, Minnesota, United States, 55805

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

MNCCTN Essentia Health Fosston

Recruiting

Fosston, Minnesota, United States, 56542

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

MNCCTN Essentia Health Hibbing Clinic

Recruiting

Hibbing, Minnesota, United States, 55746

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

Masonic Cancer Center, University of Minnesota

Recruiting

Minneapolis, Minnesota, United States, 55455

MNCCTN Essentia Health Sandstone

Recruiting

Sandstone, Minnesota, United States, 550723

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

MNCCTN Essentia Health Virginia Clinic

Recruiting

Virginia, Minnesota, United States, 55792

Contacts

Tammie Mlodozynie

Tammie.Mlodozyniec@essentiahealth.org

More Information

Sponsor

Masonic Cancer Center, University of Minnesota

Last update posted

Sep 11, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota on 2025-09-11.